drugset
drugset / Trial / NCT07475026

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

NCT07475026 ↗

Phase 3 Not yet recruiting 198 enrolled Tianjin Medical University Cancer Institute and Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, multicenter, randomized controlled, phase 3 study to explore the efficacy and safety of neoadjuvant tislelizumab plus lenvatinib in patients with resectable HCC at high risk of recurrence.

Timeline

Start
2026-05-30
Primary completion
2030-01-31
Completion
2030-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 8 mg Oral
Subject Lenvatinib Small molecule 12 mg Oral
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous

Indications

hepatocellular carcinoma